SEC Form 13F
| Report period | 2026-06-30 |
|---|---|
| Publicly available | 2026-08-14 |
| Reported value | $471,616,867 |
| Positions | 14 |
| Issuer | Ticker | Class | Reported value | Reported amount |
|---|---|---|---|---|
| BRIDGEBIO PHARMA INC | BBIO | COM | $341,834,227 | 4,589,611 |
| MONTE ROSA THERAPEUTICS INC | GLUE | COM | $37,647,069 | 1,555,664 |
| SYNDAX PHARMACEUTICALS INC | SNDX | COM | $28,785,379 | 1,316,806 |
| COMPASS PATHWAYS PLC | CMPS | SPONSORED ADS | $20,267,554 | 1,432,336 |
| BICARA THERAPEUTICS INC | BCAX | COM | $16,891,205 | 568,919 |
| BRIDGEBIO ONCOLOGY THERAPEUT | BBOT | COM NEW | $7,757,297 | 1,018,018 |
| SCHOLAR ROCK HLDG CORP | SRRK | COM | $4,236,705 | 77,031 |
| UROGEN PHARMA LTD | URGN | COM | $3,974,400 | 108,000 |
| BIOMEA FUSION INC | BMEA | COM | $3,011,673 | 2,048,757 |
| ACLARIS THERAPEUTICS INC | ACRS | COM | $2,298,267 | 434,455 |
Public filing evidence only. NexusTrade's simulated follower strategies are hypothetical, modeled results — not live trading returns and not investment advice.